Overview

A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder

Status:
Completed

Trial end date:
2006-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and effectiveness of a long-acting injectable formulation of risperidone in stable bipolar patients randomly switched from their current add-on oral antipsychotic (olanzapine, risperidone, or quetiapine) therapy to long-acting injectable risperidone. The patients switched to long-acting injectable risperidone will be compared to patients who continue on their oral antipsychotic treatment regimen

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Ortho Inc., Canada

Treatments:

Antipsychotic Agents
Risperidone